Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C.

M. Pirisi,C. Fabris,P. Toniutto,E. Falleti,S. Tisminetzky,M. Gerotto,G. Soardo,D. Vitulli,M. Del Forno,F. Baralle,E. Bartoli
Digestive Diseases and Sciences
Abstract:To verify its value with regard to the outcome of therapy in chronic hepatitis C, serum interferon-alpha (IFN) was measured by ELISA in 70 patients (43 male, 27 female) with chronic hepatitis C, treated with IFN 9 MU/week subcutaneously for up to one year. Serum IFN was detectable in 49/70 patients, 16 of whom had IFN values >125 pg/ml. Only 1/22 patients who maintained a sustained response six months after the end of treatment had pretreatment serum IFN > 125 pg/ml, in comparison to 15/48 patients who did not respond or who relapsed (chi2 6.1, P < 0.02). At multivariate analysis the predictive value of serum IFN was independent of age, sex, presence of cirrhosis, infection by genotype 1b (improvement chi2 7.1, P < 0.01). In patients with chronic hepatitis C, measurement of serum IFN at baseline might be useful for the selection of patients with higher probability of long-term response.
What problem does this paper attempt to address?